Abstract
A number of studies have demonstrated a role for transition metals and oxidative stress in the etiology of Parkinson ’ s disease (PD). Genetic and biochemical evidence also clearly links the protein alpha-synuclein (αSyn) to PD and a number of associated diseases. In these “synucleinopathies”, αSyn is deposited, often in oligomerized forms, as cytoplasmic inclusions known as Lewy bodies and Lewy neurites. αSyn cross-linking/oligomerization can occur via a number of processes, most stimulated by metal catalyzed oxidation (MCO). In PD, the increased sensitivity of midbrain neurons expressing high levels of oxidizable catecholamines may provide one clue to account for degeneration of these neurons. In other regions of the nervous system that develop Lewy body pathology, the mode of αSyn oligomerization is less clear. Thus, the relationship between αSyn and MCO, either direct or indirect, represents a particular concern for possible treatment of these various diseases.
Keywords: Parkinson's disease, alpha-synuclein, metals, oxidation, dopamine, oligomerization, cross-linking, neuromelanin
Current Alzheimer Research
Title: Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Volume: 5 Issue: 6
Author(s): N. B. Cole
Affiliation:
Keywords: Parkinson's disease, alpha-synuclein, metals, oxidation, dopamine, oligomerization, cross-linking, neuromelanin
Abstract: A number of studies have demonstrated a role for transition metals and oxidative stress in the etiology of Parkinson ’ s disease (PD). Genetic and biochemical evidence also clearly links the protein alpha-synuclein (αSyn) to PD and a number of associated diseases. In these “synucleinopathies”, αSyn is deposited, often in oligomerized forms, as cytoplasmic inclusions known as Lewy bodies and Lewy neurites. αSyn cross-linking/oligomerization can occur via a number of processes, most stimulated by metal catalyzed oxidation (MCO). In PD, the increased sensitivity of midbrain neurons expressing high levels of oxidizable catecholamines may provide one clue to account for degeneration of these neurons. In other regions of the nervous system that develop Lewy body pathology, the mode of αSyn oligomerization is less clear. Thus, the relationship between αSyn and MCO, either direct or indirect, represents a particular concern for possible treatment of these various diseases.
Export Options
About this article
Cite this article as:
Cole B. N., Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?, Current Alzheimer Research 2008; 5 (6) . https://dx.doi.org/10.2174/156720508786898523
DOI https://dx.doi.org/10.2174/156720508786898523 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry On Generating Uniform Bottom Shear Stress. Part II: Shear Stress Inducing Devices
Recent Patents on Chemical Engineering Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design RGD-based Therapy: Principles of Selectivity
Current Pharmaceutical Design SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Extracellular ATP and Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests
Current Cancer Drug Targets Extranuclear Localization of SIRT1 and PGC-1α: An Insight into Possible Roles in Diseases Associated with Mitochondrial Dysfunction
Current Molecular Medicine Amyloid-β Inhibits PDGFβ Receptor Activation and Prevents PDGF-BBInduced Neuroprotection
Current Alzheimer Research Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Current Cancer Drug Targets